There is no inherent conflict between speed and quality. High-quality studies prevent costly setbacks and generate reliable data, ultimately accelerating research programs. A low-quality study is what truly delays timelines by producing unusable or misleading results.

Extending a wearable's wear time has two major benefits beyond convenience. It lowers costs by reducing device waste and the need for frequent healthcare worker assistance. More importantly, it dramatically increases patient compliance, as a once-a-month application is far easier to adhere to than a daily routine.

While wearables generate vast amounts of health data, the medical system lacks the evidence to interpret these signals accurately for healthy individuals. This creates a risk of false positives ('incidentalomas'), causing unnecessary anxiety and hindering adoption of proactive health tech.

Clinical trials often just report success rates and discard failed devices. This is a missed opportunity. By contractually requiring failed devices to be returned, R&D teams can analyze failure modes and create representative lab tests, drastically speeding up development and avoiding expensive repeat clinicals.

To balance immediate user needs with long-term R&D, Eleven Labs uses a "3-month rule." If a foundational research solution is projected to take more than three months, the product team is empowered to ship a simpler, faster, tactical solution in the interim.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

Traditional medical adhesives designed for 7-day wear are insufficient for longer-term wearables. At around the 15-day mark, the skin's outer layer begins to significantly turn over and flake away, creating a new biological barrier that requires a fundamentally different approach to adhesive engineering.

With clinical development cycles lasting 7-10 years, junior team members rarely see a project to completion. Their career incentive becomes pushing a drug to the next stage to demonstrate progress, rather than ensuring its ultimate success. This pathology leads to deferred problems and siloed knowledge.

Instead of arguing for more time, product leaders should get stakeholder buy-in on a standardized decision-making process. The depth and rigor of each step can then be adjusted based on available time, from a two-day workshop to an eight-month study, without skipping agreed-upon stages.